Indivior Pharmaceuticals, Inc.

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 15, 2026, Indivior Pharmaceuticals, Inc. (“Indivior”) held a special meeting of its stockholders (the “Indivior Special Meeting”). At the close of business on September 4, 2026, the record date for the Indivior Special Meeting, there were 118,031,934 shares of Indivior common stock (“Indivior Shares”) outstanding and entitled to vote at the Indivior Special Meeting, of which 91,206,182 Indivior Shares were present in person or represented by proxy at the Indivior Special Meeting, representing 77.27% of Indivior Shares outstanding and entitled to vote, which constituted a quorum to conduct business at the Indivior Special Meeting. At the Indivior Special Meeting, Indivior’s stockholders approved the proposal described below and which is described in greater detail in Indivior’s definitive joint proxy statement/prospectus filed with the Securities and Exchange Commission on September 11, 2026. Stockholder action on a second proposal, to approve one or more adjournments of the Indivior Special Meeting to a later date or time, if necessary or appropriate, including adjournments to permit the solicitation of additional votes or proxies in favor of the Indivior Share Issuance Proposal (as defined below) if there are insufficient votes at the time of such adjournment to approve such proposal, was not required and no vote was taken on that proposal. The final voting results with respect to the proposal considered and voted upon at the Indivior Special Meeting are set forth below. Proposal 1: Indivior Share Issuance. To approve the issuance of the Indivior Shares in connection with the Merger as contemplated by the Merger Agreement, including for purposes of complying with the applicable provisions of Nasdaq Rule 5635 (the “Indivior Share Issuance Proposal”). For Against Abstain Broker Non-Vote ─────────────────────────────────────────────────────────────── 85,455,705 5,563,744 186,733 N/A